The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer

About half of all patients with non-small cell lung cancer (NSCLC) have metastatic disease at first presentation [1 –3]. Furthermore, many patients with local or locally advanced NSCLC will develop metachronous metastasis during the course of the disease [4,5]. Metastatic NSCLC is considered incurable with a high cancer related mortality rate [6–8]. Although survival has improved with the introduction of immu notherapy for advanced (stage IV) NSCLC, the disease will eventually progress [9–11]. For some patients, disease progression is limited to the primary tumour or to one or only a few distant metastasis i.e.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research